iN Therapeutics secures $500m pain drug license deal with US biotech

iN Therapeutics, a spin-off from Daewoong Pharmaceuticals, said Thursday it has inked a license-out agreement worth up to $500 million with US-based Niroda Therapeutics for its Aneratrigine, a next-generation non-opioid pain treatment candidate. The Korean biotech said it has secured upfront payment without disclosing the exact amount, adding that it plans to secure step-by-step milestones and royalties in the next 18 months. According to iN Therapeutics, Aneratrigine is designed to selectively